Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 5 (2008), Issue 3 (March)

1. Surviving recurrence: psychological and quality-of-life recovery.
   Cancer, 112(5): 1178-87. [Abstract] [Full-text]
2. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
   Cancer, 112(5): 1001-10. [Abstract] [Full-text]
3. Determinants of breast cancer knowledge among newly diagnosed, low-income, medically underserved women with breast cancer.
   Cancer, 112(5): 1153-61. [Abstract] [Full-text]
4. Is mode of breast cancer detection associated with cancer treatment in the United States?
   Cancer, 112(5): 1011-9. [Abstract] [Full-text]
5. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
   Cancer, 112(5): 995-1000. [Abstract] [Full-text]
6. Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity.
   Semin Radiat Oncol, 18(2): 105-14. [Abstract] [Full-text]
7. Polymorphisms in XPC and ERCC2 genes, smoking and breast cancer risk.
   Int J Cancer, 122(9): 2101-5. [Abstract] [Full-text]
8. International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers.
   Int J Cancer, 122(9): 2017-22. [Abstract] [Full-text]
9. Apoptosis of estrogen-receptor negative breast cancer and colon cancer cell lines by PTP alpha and src RNAi.
   Int J Cancer, 122(9): 1999-2007. [Abstract] [Full-text]
10. 17beta-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer.
    Int J Cancer, 122(9): 1931-40. [Abstract] [Full-text]
11. Coffee, tea, caffeine and risk of breast cancer: a 22-year follow-up.
    Int J Cancer, 122(9): 2071-6. [Abstract] [Full-text]
12. Increased antitumor potential of the raloxifene prodrug, raloxifene diphosphate.
    Int J Cancer, 122(9): 2142-7. [Abstract] [Full-text]
13. Acrylamide exposure and incidence of breast cancer among postmenopausal women in the Danish Diet, Cancer and Health Study.
    Int J Cancer, 122(9): 2094-100. [Abstract] [Full-text]
14. Prognostic significance of MMP-9 and TIMP-1 serum and tissue expression in breast cancer.
    Int J Cancer, 122(9): 2050-6. [Abstract] [Full-text]
15. The combination of epigallocatechin gallate and curcumin suppresses ER alpha-breast cancer cell growth in vitro and in vivo.
    Int J Cancer, 122(9): 1966-71. [Abstract] [Full-text]
16. The molecular etiology of breast cancer: evidence from biomarkers of risk.
    Int J Cancer, 122(9): 1949-57. [Abstract] [Full-text]
17. Redesigned gluteal artery perforator flap for breast reconstruction.
    Plast Reconstr Surg, 121(3): 728-34. [Abstract] [Full-text]
18. Assessment of immediate conservative breast surgery reconstruction: a classification system of defects revisited and an algorithm for selecting the appropriate technique.
    Plast Reconstr Surg, 121(3): 716-27. [Abstract] [Full-text]
19. Neurofibromatosis: a cause of prepubertal gynecomastia.
    Plast Reconstr Surg, 121(3): 34e-40e. [Abstract] [Full-text]
20. A pilot study of predictive markers of chemotherapy-related amenorrhea among premenopausal women with early stage breast cancer.
    Cancer Invest, 26(3): 286-95. [Abstract] [Full-text]
21. Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer.
    Cancer Invest, 26(3): 250-5. [Abstract] [Full-text]
22. OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative).
    Cancer Invest, 26(3): 222-9. [Abstract] [Full-text]
23. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
    Cancer Res, 68(5): 1538-45. [Abstract] [Full-text]
24. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Cancer Res, 68(5): 1504-12. [Abstract] [Full-text]
25. Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells.
    Cancer Res, 68(5): 1471-7. [Abstract] [Full-text]
26. Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling.
    Cancer Res, 68(5): 1388-97. [Abstract] [Full-text]
27. A human breast cell model of preinvasive to invasive transition.
    Cancer Res, 68(5): 1378-87. [Abstract] [Full-text]
28. Oncogene-mediated inhibition of glycogen synthase kinase 3 beta impairs degradation of prolactin receptor.
    Cancer Res, 68(5): 1354-61. [Abstract] [Full-text]
29. An actin-binding protein Girdin regulates the motility of breast cancer cells.
    Cancer Res, 68(5): 1310-8. [Abstract] [Full-text]
30. Sentinel node procedure is warranted in ductal carcinoma in situ with high risk of occult invasive carcinoma and microinvasive carcinoma treated by mastectomy.
    Breast J, 14(2): 135-40. [Abstract] [Full-text]
31. Treatment variation by insurance status for breast cancer patients.
    Breast J, 14(2): 128-34. [Abstract] [Full-text]
32. Pathological, clinical and prognostic characteristics of breast cancer in Central Sudan versus Northern Italy: implications for breast cancer in Africa.
    Histopathology, 52(4): 445-56. [Abstract] [Full-text]
33. Time trends in the outcome of elderly patients with breast cancer.
    Breast J, 14(2): 158-63. [Abstract] [Full-text]
34. Experiences with weight change in African-American breast cancer survivors.
    Breast J, 14(2): 182-7. [Abstract] [Full-text]
35. Casein Kinase I epsilon positively regulates the Akt pathway in breast cancer cell lines.
    Biochem Biophys Res Commun, 368(3): 801-7. [Abstract] [Full-text]
36. 17beta-Estradiol inhibits osteoprotegerin production by the estrogen receptor-alpha-positive human breast cancer cell line MCF-7.
    Biochem Biophys Res Commun, 368(3): 736-41. [Abstract] [Full-text]
37. Significance of intramammary lymph nodes in the staging of breast cancer: correlation with tumor characteristics and outcome.
    Breast J, 14(2): 147-52. [Abstract] [Full-text]
38. A multi-site validation trial of radioactive seed localization as an alternative to wire localization.
    Breast J, 14(2): 153-7. [Abstract] [Full-text]
39. Invasive apocrine carcinoma of the breast: clinicopathologic features of 57 patients.
    Breast J, 14(2): 164-8. [Abstract] [Full-text]
40. Computed tomography-guided localization of breast lesions.
    Breast J, 14(2): 169-75. [Abstract] [Full-text]
41. Breast cancer and sexuality.
    Breast J, 14(2): 176-81. [Abstract] [Full-text]
42. Problems with the use of breast conservation therapy for breast cancer in a patient with neurofibromatosis type 1: a case report.
    Breast J, 14(2): 188-92. [Abstract] [Full-text]
43. Intraductal fibroadenomatosis: an unusual variant of fibroadenoma.
    Breast J, 14(2): 193-5. [Abstract] [Full-text]
44. The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.
    Breast J, 14(2): 141-6. [Abstract] [Full-text]
45. Promoting regular mammography screening II. Results from a randomized controlled trial in US women veterans.
    J Natl Cancer Inst, 100(5): 347-58. [Abstract] [Full-text]
46. Promoting regular mammography screening I. A systematic assessment of validity in a randomized trial.
    J Natl Cancer Inst, 100(5): 333-46. [Abstract] [Full-text]
47. Wage losses in the year after breast cancer: extent and determinants among Canadian women.
    J Natl Cancer Inst, 100(5): 321-32. [Abstract] [Full-text]
48. Postoperative sense of well-being and quality of life in breast cancer patients do not depend on type of primary surgery.
    Onkologie, 31(3): 99-104. [Abstract] [Full-text]
49. RHEB expression in fibroadenomas of the breast.
    Pathol Int, 58(4): 226-32. [Abstract] [Full-text]
50. Predictors of depressed mood in spouses of women with breast cancer.
    J Clin Oncol, 26(8): 1289-95. [Abstract] [Full-text]
51. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer.
    J Clin Oncol, 26(8): 1260-8. [Abstract] [Full-text]
52. Treatment of advanced hormone-sensitive breast cancer in postmenopausal women with exemestane alone or in combination with celecoxib.
    J Clin Oncol, 26(8): 1253-9. [Abstract] [Full-text]
53. Risk of new primary nonbreast cancers after breast cancer treatment: a Dutch population-based study.
    J Clin Oncol, 26(8): 1239-46. [Abstract] [Full-text]
54. The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.
    J Clin Oncol, 26(8): 1216-22. [Abstract] [Full-text]
55. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.
    J Clin Oncol, 26(8): 1208-15. [Abstract] [Full-text]
56. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
    J Clin Oncol, 26(8): 1331-7. [Abstract] [Full-text]
57. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast.
    J Clin Oncol, 26(8): 1247-52. [Abstract] [Full-text]
58. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial.
    J Clin Oncol, 26(8): 1231-8. [Abstract] [Full-text]
59. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
    J Clin Oncol, 26(8): 1275-81. [Abstract] [Full-text]
60. Late cardiac effects of adjuvant chemotherapy in breast cancer survivors treated on Southwest Oncology Group protocol s8897.
    J Clin Oncol, 26(8): 1223-30. [Abstract] [Full-text]
61. MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA.
    Oncogene, 27(11): 1645-9. [Abstract] [Full-text]
62. Prediction of breast cancer and lymph node metastatic status with tumour markers using logistic regression models.
    J Eval Clin Pract, 14(2): 275-80. [Abstract] [Full-text]
63. Nuclear export of BRCA1 occurs during early S phase and is calcium-dependent.
    Cell Signal, 20(5): 958-68. [Abstract] [Full-text]
64. Staying the distance: avoiding the proteasomal trap.
    Cancer Cell, 13(3): 184-5. [Abstract] [Full-text]
65. PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53.
    Cancer Genet Cytogenet, 182(1): 33-9. [Abstract] [Full-text]
66. A Bayesian derived network of breast pathology co-occurrence.
    J Biomed Inform, 41(2): 242-50. [Abstract] [Full-text]
67. Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer.
    Br J Surg, 95(4): 433-7. [Abstract] [Full-text]
68. Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner.
    Mol Cell Biol, 28(7): 2235-43. [Abstract] [Full-text]
69. Impact of aging on the biology of breast cancer.
    Crit Rev Oncol Hematol, 66(1): 65-74. [Abstract] [Full-text]
70. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety.
    Crit Rev Oncol Hematol, 66(1): 31-41. [Abstract] [Full-text]
71. Screening mammography in older women. Effect of wealth and prognosis.
    Arch Intern Med, 168(5): 514-20. [Abstract] [Full-text]
72. The genomic heritage of lymph node metastases: implications for clinical management of patients with breast cancer.
    Ann Surg Oncol, 15(4): 1056-63. [Abstract] [Full-text]
73. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma.
    Ann Surg Oncol, 15(4): 1070-80. [Abstract] [Full-text]
74. A prospective longitudinal study of cosmetic outcome in immediate latissimus dorsi breast reconstruction and the influence of radiotherapy.
    Ann Surg Oncol, 15(4): 1081-91. [Abstract] [Full-text]
75. Axillary and extra-axillary lymph node recurrences after a tumor-negative sentinel node biopsy for breast cancer using intralesional tracer administration.
    Ann Surg Oncol, 15(4): 1025-31. [Abstract] [Full-text]
76. The possible association between IVF and breast cancer incidence.
    Ann Surg Oncol, 15(4): 1048-55. [Abstract] [Full-text]
77. Surgical follow-up and clinical presentation of 142 breast papillary lesions diagnosed by ultrasound-guided core-needle biopsy.
    Ann Surg Oncol, 15(4): 1040-7. [Abstract] [Full-text]
78. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients.
    Ann Surg Oncol, 15(4): 1064-9. [Abstract] [Full-text]
79. Outpatient mastectomy and breast reconstructive surgery.
    Ann Surg Oncol, 15(4): 1032-9. [Abstract] [Full-text]
80. The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer.
    Carcinogenesis, 29(3): 510-8. [Abstract] [Full-text]
81. Flexible laryngeal mask as an alternative to reinforced tracheal tube for upper chest, head and neck oncoplastic surgery.
    Eur J Anaesthesiol, 25(4): 261-6. [Abstract] [Full-text]
82. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Carcinogenesis, 29(3): 473-9. [Abstract] [Full-text]
83. Weekly epoetin beta maintains haemoglobin levels and improves quality of life in patients with non-myeloid malignancies receiving chemotherapy.
    Jpn J Clin Oncol, 38(3): 214-21. [Abstract] [Full-text]
84. Clinical efficacy of S-1 in pretreated metastatic breast cancer patients.
    Jpn J Clin Oncol, 38(3): 172-5. [Abstract] [Full-text]
85. Electromagnetic fields alter the expression of estrogen receptor cofactors in breast cancer cells.
    Bioelectromagnetics, 29(3): 169-76. [Abstract] [Full-text]
86. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis.
    Nature, 452(7184): 187-93. [Abstract] [Full-text]
87. Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.
    Oncogene, 27(12): 1805-11. [Abstract] [Full-text]
88. AXL is a potential target for therapeutic intervention in breast cancer progression.
    Cancer Res, 68(6): 1905-15. [Abstract] [Full-text]
89. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells.
    Cancer Res, 68(6): 1881-8. [Abstract] [Full-text]
90. Epithelial progeny of estrogen-exposed breast progenitor cells display a cancer-like methylome.
    Cancer Res, 68(6): 1786-96. [Abstract] [Full-text]
91. 14-3-3 zeta down-regulates p53 in mammary epithelial cells and confers luminal filling.
    Cancer Res, 68(6): 1760-7. [Abstract] [Full-text]
92. Rad6B is a positive regulator of beta-catenin stabilization.
    Cancer Res, 68(6): 1741-50. [Abstract] [Full-text]
93. BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer.
    Cancer Res, 68(6): 1667-74. [Abstract] [Full-text]
94. Laminin 5 expression in metaplastic breast carcinomas.
    Am J Surg Pathol, 32(3): 345-53. [Abstract] [Full-text]
95. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer.
    Cancer Lett, 262(2): 232-8. [Abstract] [Full-text]
96. An investigation into methods of IMRT planning applied to breast radiotherapy.
    Br J Radiol, 81(964): 311-22. [Abstract] [Full-text]
97. Case report: Second primary small cell carcinoma of the trachea in a breast cancer survivor: a case report and literature review.
    Br J Radiol, 81(964): e120-2. [Abstract] [Full-text]
98. Prognostic significance of intratumoral and peritumoral lymphatic density and blood vessel density in invasive breast carcinomas.
    Am J Clin Pathol, 129(4): 578-86. [Abstract] [Full-text]
99. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
    Am J Clin Pathol, 129(4): 563-70. [Abstract] [Full-text]
100. Prognostic differences of World Health Organization-assessed mitotic activity index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years.
     Hum Pathol, 39(4): 584-90. [Abstract] [Full-text]
101. Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions.
     Hum Pathol, 39(4): 616-22. [Abstract] [Full-text]
102. Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?
     Hum Pathol, 39(4): 506-13. [Abstract] [Full-text]
103. Live item index technique: an intervention research tool.
     Nurs Res, 57(2): 69-74. [Abstract] [Full-text]
104. The role of radiotherapy in treating small early invasive breast cancer.
     Eur J Surg Oncol, 34(4): 369-76. [Abstract] [Full-text]
105. The feasibility of sentinel node biopsy in the previously treated breast.
     Eur J Surg Oncol, 34(4): 365-8. [Abstract] [Full-text]
106. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users.
     J Clin Oncol, 26(9): 1537-43. [Abstract] [Full-text]
107. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
     J Clin Oncol, 26(9): 1404-10. [Abstract] [Full-text]
108. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
     J Clin Oncol, 26(9): 1419-26. [Abstract] [Full-text]
109. Oral contraceptives, postmenopausal hormones, and risk of asynchronous bilateral breast cancer: the WECARE Study Group.
     J Clin Oncol, 26(9): 1411-8. [Abstract] [Full-text]
110. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer.
     J Natl Cancer Inst, 100(6): 421-7. [Abstract] [Full-text]
111. Association of a common AKAP9 variant with breast cancer risk: a collaborative analysis.
     J Natl Cancer Inst, 100(6): 437-42. [Abstract] [Full-text]
112. Coexistence of carcinoma and tuberculosis in one breast.
     World J Surg Oncol, 6: 29. [Abstract] [Full-text]
113. Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions.
     Diagn Mol Pathol, 17(1): 28-33. [Abstract] [Full-text]
114. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients.
     Pharmacogenomics J, 8(2): 139-46. [Abstract] [Full-text]
115. Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33.
     Proc Natl Acad Sci U S A, 105(11): 4340-5. [Abstract] [Full-text]
116. Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent.
     Hum Genet, 123(3): 247-55. [Abstract] [Full-text]
117. Immediate latissimus dorsi/prosthetic breast reconstruction following salvage mastectomy after failed lumpectomy/irradiation.
     Plast Reconstr Surg, 121(4): 159e-64e. [Abstract] [Full-text]
118. Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1.
     Oncogene, 27(13): 1886-93. [Abstract] [Full-text]
119. Phosphorylation of nm23-H1 by CKI induces its complex formation with h-prune and promotes cell motility.
     Oncogene, 27(13): 1853-64. [Abstract] [Full-text]
120. Digital breast tomosynthesis: a pilot observer study.
     AJR Am J Roentgenol, 190(4): 865-9. [Abstract] [Full-text]
121. Comparison of computer-aided detection to double reading of screening mammograms: review of 231,221 mammograms.
     AJR Am J Roentgenol, 190(4): 854-9. [Abstract] [Full-text]
122. The Yin and Yang of treating BRCA-deficient tumors.
     Cell, 132(6): 919-20. [Abstract] [Full-text]
123. Results of a survey on digital screening mammography: prevalence, efficiency, and use of ancillary diagnostic AIDS.
     J Am Coll Radiol, 5(4): 585-92. [Abstract] [Full-text]
124. A comprehensive genetic profile of phyllodes tumours of the breast detects important mutations, intra-tumoral genetic heterogeneity and new genetic changes on recurrence.
     J Pathol, 214(5): 533-44. [Abstract] [Full-text]
125. Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancer.
     Biochim Biophys Acta, 1782(4): 259-70. [Abstract] [Full-text]
126. Endothelial cells and normal breast epithelial cells enhance invasion of breast carcinoma cells by CXCR-4-dependent up-regulation of urokinase-type plasminogen activator receptor (uPAR, CD87) expression.
     J Pathol, 214(5): 545-54. [Abstract] [Full-text]
127. Clinical trial priorities among surgeons caring for breast cancer patients.
     Am J Surg, 195(4): 474-80. [Abstract] [Full-text]
128. Changing indications for surgery in patients with stage IV breast cancer: a current perspective.
     Cancer, 112(7): 1445-54. [Abstract] [Full-text]
129. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
     Cancer, 112(7): 1455-61. [Abstract] [Full-text]
130. Induction of vascular endothelial growth factor by peptidyl-prolyl isomerase Pin1 in breast cancer cells.
     Biochem Biophys Res Commun, 369(2): 547-53. [Abstract] [Full-text]
131. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
     Cancer, 112(7): 1437-44. [Abstract] [Full-text]
132. Ixabepilone, a novel epothilone analog in the treatment of breast cancer.
     Expert Opin Investig Drugs, 17(4): 593-9. [Abstract] [Full-text]
133. Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer.
     Proc Natl Acad Sci U S A, 105(12): 4850-5. [Abstract] [Full-text]
134. p27 and Skp2 immunoreactivity and its clinical significance with endocrine and chemo-endocrine treatments in node-negative early breast cancer.
     Ann Oncol, 19(4): 660-8. [Abstract] [Full-text]
135. The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited.
     Ann Oncol, 19(4): 655-9. [Abstract] [Full-text]
136. Metastases to the breast: role of fine needle cytology samples. Our experience with nine cases in 2 years.
     Ann Oncol, 19(4): 682-7. [Abstract] [Full-text]
137. Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers.
     Ann Oncol, 19(4): 649-54. [Abstract] [Full-text]
138. Preoperative CA 15-3 and CEA serum levels as predictor for breast cancer outcomes.
     Ann Oncol, 19(4): 675-81. [Abstract] [Full-text]
139. European guidelines for quality assurance in breast cancer screening and diagnosis. Fourth edition--summary document.
     Ann Oncol, 19(4): 614-22. [Abstract] [Full-text]
140. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer.
     Ann Oncol, 19(4): 669-74. [Abstract] [Full-text]
141. Emerging therapeutic options for breast cancer chemotherapy during pregnancy.
     Ann Oncol, 19(4): 607-13. [Abstract] [Full-text]
142. Review of the etiology of breast cancer with special attention to organochlorines as potential endocrine disruptors.
     J Toxicol Environ Health B Crit Rev, 11(3): 276-300. [Abstract] [Full-text]
143. Clinical impact of oncoplastic surgery in a specialist breast practice.
     ANZ J Surg, 78(4): 269-72. [Abstract] [Full-text]
144. Percutaneous microductectomy with a directional vacuum-assisted system guided by ultrasonography for the treatment of breast discharge: experience in 63 cases.
     Acta Radiol, 49(3): 271-6. [Abstract] [Full-text]
145. Needle tract seeding after vacuum-assisted breast biopsy.
     Acta Radiol, 49(3): 267-70. [Abstract] [Full-text]
146. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT.
     Radiology, 247(1): 189-96. [Abstract] [Full-text]
147. Accuracy of soft-copy digital mammography versus that of screen-film mammography according to digital manufacturer: ACRIN DMIST retrospective multireader study.
     Radiology, 247(1): 38-48. [Abstract] [Full-text]
148. Use of intraoperative stereomicroscopy for preventing loss of metastases during frozen sectioning of sentinel lymph nodes in breast cancer.
     Histopathology, 52(5): 597-604. [Abstract] [Full-text]
149. Mutation analysis and characterization of HSD17B2 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.
     J Mol Endocrinol, 40(4): 161-72. [Abstract] [Full-text]
150. Occurrence of synchronous invasive lobular breast carcinoma and poorly differentiated ovarian carcinoma in a single peritoneal deposit.
     Oncology, 73(1): 136-40. [Abstract] [Full-text]
151. Wnt signaling pathway in invasive ductal carcinoma of the breast: relationship between beta-catenin, dishevelled and cyclin D1 expression.
     Oncology, 73(1): 112-7. [Abstract] [Full-text]
152. Expression of periostin in human breast cancer.
     J Clin Pathol, 61(4): 494-8. [Abstract] [Full-text]
153. Economic evaluation alongside a clinical trial of psycho-educational interventions to improve adjustment to survivorship among patients with breast cancer.
     J Clin Oncol, 26(10): 1684-90. [Abstract] [Full-text]
154. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
     J Clin Oncol, 26(10): 1671-6. [Abstract] [Full-text]
155. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators.
     J Clin Oncol, 26(10): 1657-63. [Abstract] [Full-text]
156. Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.
     J Clin Oncol, 26(10): 1650-6. [Abstract] [Full-text]
157. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.
     J Clin Oncol, 26(10): 1642-9. [Abstract] [Full-text]
158. Oestrogen and the colon: potential mechanisms for cancer prevention.
     Lancet Oncol, 9(4): 385-91. [Abstract] [Full-text]
159. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
     Lancet Oncol, 9(4): 331-41. [Abstract] [Full-text]
160. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
     Lancet, 371(9618): 1098-107. [Abstract] [Full-text]
161. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.
     J Clin Oncol, 26(10): 1664-70. [Abstract] [Full-text]
162. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group.
     J Clin Oncol, 26(10): 1677-83. [Abstract] [Full-text]
163. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer.
     J Clin Oncol, 26(10): 1691-7. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.